Guggenheim Capital’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Guggenheim Capital’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-403,032	Closed	-$21.7M	–	2838
2017 Q4	$21.7M	Buy	403,032 +31,964	+9%	+$1.75M	0.05%	523
2017 Q3	$21.2M	Buy	371,068 +8,787	+2%	+$515K	0.05%	530
2017 Q2	$21.8M	Buy	362,281 +10,069	+3%	+$573K	0.06%	526
2017 Q1	$19.2M	Buy	+352,212	New	+$17.3M	0.05%	529

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Guggenheim Capital's BIVV Position: Q1 2018 in Review

Guggenheim Capital sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 403,032 shares — an estimated $21.7M sold.

Guggenheim Capital first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $21.8M in Q2 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Guggenheim Capital reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Guggenheim Capital sold 403,032 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $21.7M.
Guggenheim Capital first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Guggenheim Capital's Bioverativ Inc. Common Stock position peaked at $21.8M in Q2 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Guggenheim Capital's 13F filing for Q1 2018, filed 15 May 2018.